Adalta Ltd. · ASX:1AD
Adalta — Biotech Meets Broker September 2016
15 slides from Adalta's conference presentation, Sep 8, 2016
Slide 1: i-bodies – a new class of protein therapeutics to treat human disease
For personal use only i-bodies – a new class of protein therapeutics to treat human disease Biotech meets Broker: September 2016 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au
Slide 2: Disclaimer
Disclaimer For personal use only Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or in
Slide 3: Corporate and investment summary
Corporate and investment summary A drug discovery and development company For personal use only Capital structure focused on using its proprietary technology ASX code 1AD platform to generate a new class of protein Shares on issue* 100m therapeutics, known as i-bodies, for treating a Share price (6
Slide 4: i-body technology
i-body technology Long loop that enables access to For personal use only AdAlta is developing a new technology platform that produces novel drug targets unique proteins known as i-bodies, that mimic the shape of shark antibody binding domain and engineers their key stability features into a human pr
Slide 5: Fibrosis: unmet medical need with multiple indications
Fibrosis: unmet medical need with multiple indications For personal use only Developing i-bodies as improved therapies for the treatment of fibrosis – a condition that is prevalent in 45-50% of all diseases Fibrosis can occur in many tissues of the body Lung Eye Liver as a result of inflammation or
Slide 6: AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF)
AD-114 lead program in Idiopathic Pulmonary Fibrosis (IPF) For personal use only AD-114 is lead i-body candidate in pre-clinical development – Demonstrates both anti-fibrotic and anti-inflammatory activity in the lung – Important for arresting and modifying the disease and tackling the treatment of
Slide 7: AD-114 prevents lung fibrosis in disease models
AD-114 prevents lung fibrosis in disease models For personal use only Extensive pre-clinical AD-114 studies have demonstrated positive in vitro (in the lab) and in vivo (in animals) data Normal IPF lung tissue IPF lung tissue + AD-114 lung tissue (lung disease mouse model) dosed for 21 days (lung di
Slide 8: AD-114 key advantages compared to existing IPF treatments
AD-114 key advantages compared to existing IPF treatments For personal use only AD-114 has greater in vitro efficacy compared to the only approved therapies Nintedanib and Pirfenidone for IPF No effect Effect on Human tissue treatment on normal diseased / In vitro activity tissue IPF tissue – Existi
Slide 9: Global market interest in fibrosis treatments
Global market interest in fibrosis treatments Recent transactions confirm that big pharma are actively acquiring fibrosis assets at For personal use only an early stage – typically based on Phase I results Date Company Target Acquired by Deal value (US$) Deal commentary Sep-15 Adheron SDP051 Roche $
Slide 10: AD-114 development: key milestones
AD-114 development: key milestones For personal use only CY2016 CY2017 CY2018 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Partnering of lead Manufacturing of lead candidate candidate based on other Toxicology studies benchmark deals Orphan designation Phase I Publication of data Other fibrosis indications BD and partne
Slide 11: Expected newsflow next months
Expected newsflow next 18 months For personal use only Q3 2016 Orphan Drug Designation (US FDA) Commence manufacturing of material for toxicology testing Presentation at Discovery on Target, Boston Q4 2016 Additional AD-114 IPF fibrosis data Hypertrophic scarring animal results for AD-114 Completion
Slide 12: AdAlta business model – strategy to create value
AdAlta business model – strategy to create value For personal use only Pharma & biotech partnerships Revenues: Upfronts, i-body FTEs, milestones & royalties i-bodies new technology drug class platform and Potential in multiple library In-house disease indications Licence to pipeline of pharma drug R
Slide 13: Market benchmarks
Market benchmarks For personal use only Fibrosis lead AD-114 Sep-15 acquired by Roche Aug-15 acquired by BMS Nov-14 acquired by BMS $105m + $475m milestones $150m + $1.25b milestones $444m phase I asset phase IIa asset phase I asset Next gen antibodies April-16 with Abbvie Dec -15 with Roche Nov-15
Slide 14: Management and Board in place to deliver strategy
Management and Board in Internationally recognised SAB with proven track place to deliver strategy For personal use only record of drug development Sam Cobb: Founding Dr John Chiplin: David McGibney: pre-clinical CEO and Director Independent Director and clinical advisor Extensive experience in rais
Slide 15: AdAlta investment summary
AdAlta investment summary For personal use only Powerful proprietary technology platform to develop a pipeline of i-bodies for the treatment of a wide range of human diseases Initial focus on treating Idiopathic Pulmonary Fibrosis and other fibrotic diseases - high unmet clinical need Advanced lead